An aging population both in the US and worldwide isn’t just a demographic trend, it’s a massive economic shift.
As millions of baby boomers retire and life expectancy rises, demand is surging for everything from healthcare and senior living to medical devices and prescription drugs.
This opens the door for people to partake in this long-term trend by investing in companies that are built to serve the needs of older adults.
Here are 10 stocks that are currently positioned to benefit from the global trend toward an aging population.
Biogen (BIIB)
- Market Cap: $17.5 billion
- Industry: Biotechnology
- Analyst Upside: 63%
- P/E Ratio: 7.4
Company Overview: Biogen is a biotechnology company focused on treatments for neurological and neurodegenerative diseases. Its portfolio includes therapies for multiple sclerosis, spinal muscular atrophy, and Alzheimer’s, with key products like Spinraza and Leqembi.
Business Overview: Biogen generates revenue through the sale of specialized therapies and aims to expand by developing breakthrough treatments in neuroscience and partnering with other biotech innovators. The company is shifting focus from mature drugs to next-gen pipeline opportunities and strategic M&A.
Recent Developments:
- Earnings & Profitability: Biogen’s earnings have been under pressure as legacy drug sales decline, but new launches like Leqembi are starting to offset some of the slowdown.
- Business Growth Trends: The company is refocusing its pipeline around Alzheimer’s, ALS, and depression, while trimming costs and reprioritizing R&D to boost efficiency.
- Shareholder Returns: The stock’s valuation reflects uncertainty around future growth. Today, the stock may appeal to investors looking for a turnaround story with upside tied to successful new treatments.
Track Biogen’s financials, growth trends, and analyst forecasts on TIKR >>>
Dexcom, Inc. (DXCM)
- Market Cap: $26 billion
- Industry: Health Care Equipment and Supplies
- Analyst Upside: 48%
- P/E Ratio: 32.7
Company Overview: Dexcom is a medical device company best known for its continuous glucose monitoring (CGM) systems, which help people with diabetes manage their blood sugar in real time. Its flagship product line includes the G7 system, which is gaining traction globally.
Business Strategy: Dexcom makes money by selling CGM devices and recurring sensors, with a focus on expanding access and adoption through innovation and affordability. The company is also moving into broader healthcare markets by promoting CGM use beyond just Type 1 diabetes.
Recent Developments:
- Earnings & Profitability: Dexcom continues to grow revenue at a strong pace, driven by rising adoption of its G7 system and steady expansion into new geographies.
- Business Growth Trends: Management is focused on improving margins while investing in R&D and direct-to-consumer marketing to build long-term brand strength.
- Shareholder Returns: The stock trades at a premium to traditional med-tech peers, but investors are betting on the company’s potential to keep expanding in a growing, underpenetrated market.
Find stocks that we like today even better than Dexcom with TIKR >>>
Stryker Corporation (SYK)
- Market Cap: $135 billion
- Industry: Health Care Equipment and Supplies
- Analyst Upside: 19%
- P/E Ratio: 26.0
Company Overview: Stryker is a global medical technology company that makes surgical equipment, joint replacement implants, and neurotechnology devices. Its business spans orthopedics, medical and surgical equipment, and spine-related solutions.
Business Strategy: Stryker earns revenue by selling high-margin medical devices and equipment to hospitals and surgery centers, with a steady stream of recurring sales from implants and instruments. The company focuses on innovation and scale to drive growth in both developed and emerging markets.
Recent Developments:
- Earnings & Profitability: Stryker recently reported strong earnings, with higher procedure volumes and steady demand for joint replacements boosting top-line results.
- Business Growth Trends: The company continues to invest in robotics and digital surgery platforms, which are helping expand its competitive edge in the orthopedic space.
- Shareholder Returns: The stock’s valuation today is on the higher side, but long-term investors see Stryker as a reliable compounder with steady growth and solid returns over time.
Analyze long-term compounders like Stryker quicker with TIKR >>>
TIKR Takeaway
These 10 companies are set to benefit from long-term demographic tailwinds, which might make them worth a closer look for investors looking to take part in this investing theme.
- Looking for stocks with long-term growth potential? Browse TIKR’s stock screener to find the best stocks to buy today.
- Already love the stocks you own? Get real-time news and in-depth stock insights when you add your holdings to your watchlist on TIKR.
- Want to stay ahead? TIKR’s analysts’ estimates give you 5 years of Wall Street forecasts so you can feel confident in the stocks you invest in.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
